HYBRID EVENT: Join us in person in Singapore or attend virtually from anywhere.

3rd Edition of International Cancer & Immuno-Oncology Conference

March 15-17, 2027 | Singapore
March 15-17, 2027 | Singapore

Medulloblastoma

Medulloblastoma

Medulloblastoma, a highly malignant primary brain tumor, predominantly affects children and poses significant challenges in cancer research. Advances in genetic and molecular profiling have revolutionized our understanding, revealing distinct subgroups with unique prognoses and therapeutic responses. Research focuses on identifying novel biomarkers for early detection and targeted therapies to improve survival rates while minimizing long-term side effects. Cutting-edge studies explore the tumor microenvironment, aiming to disrupt supportive cellular interactions that facilitate tumor growth. Immunotherapy, including checkpoint inhibitors and CAR-T cell therapy, is emerging as a promising approach. By leveraging these scientific advancements, researchers strive to develop more precise, less toxic treatments, offering hope for better outcomes in medulloblastoma patients.

Committee Members
Committee Member - Michael Thompson

Michael Thompson

University of Toronto, Canada
Committee Member - Pietro Salvatori

Pietro Salvatori

Formerly, Humanitas San Pio X Hospital, Italy
Committee Member - Rajvir Dahiya

Rajvir Dahiya

University of California San Francisco, United States

Submit your abstract Today

YouTube
WhatsAppWhatsApp